Evidence supports the use of N-acetylcysteine (NAC) for preventing contrast-induced nephropathy (CIN), according to the findings of a new systematic review and trial sequential analysis.

The review included 43 randomized controlled trials enrolling a total of 3,277 patients who underwent coronary angiography with or without percutaneous coronary intervention.

The NAC patients had a significant 34% decreased odds of CIN compared with controls, researchers Nelson Wang, MD, of Macquarie University in Sydney, Australia, and colleagues reported in the International Journal of Cardiology (2016;209:319-327).

Continue Reading